Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use-Reference-Cited by-同舟云学术

Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

Published:2020-08-17 Issue:5 Volume:41 Page:2775-2803
ISSN:0198-6325
Container-title:Medicinal Research Reviews
language:en
Short-container-title:Med Res Rev

Author:

Gavrilova Svetlana I.¹^ORCID,Alvarez Anton²³

Affiliation:

1. Department of Geriatric Psychiatry, Cognitive Disorders and Alzheimer's Disease Unit Mental Health Research Center Moscow Russia

2. Department of Neuropsychiatry Medinova Institute of Neurosciences, Clinica RehaSalud A Coruña Spain

3. Clinical Research Department QPS Holdings A Coruña Spain

Publisher

Wiley

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/med.21722

Reference263 articles.

1. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies

2. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

3. PrinceM WimoA GuerchetM AliG‐C WuY‐T PrimaM.World Alzheimer Report 2015: The Global Impact of Dementia: an analysis of prevalence incidence cost and trends. London UK: Alzheimer's Disease International; 2015.https://www.alz.co.uk/research/world-report-2015. Accessed August 13 2020.

4. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II

5. Incidence of Dementia over Three Decades in the Framingham Heart Study

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebroprotein hydrolysate-I ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via the p53/SAT1/ALOX15 signalling pathway;European Journal of Pharmacology;2024-09

2. Efficacy and safety of butylphthalide in patients with mild cognitive impairment: a multicentre, randomised, double-blind, placebo-controlled trial (EBMCI study);BMJ Open;2024-07

3. Nature's Toolbox for Alzheimer's Disease: A Review on the Potential of Natural Products as Alzheimer's Disease Drugs;Neurochemistry International;2024-06

4. Optimization of supercritical fluid extraction of bioactive compounds from Ammodaucus leucotrichus fruits by using multivariate response surface methodology;The Journal of Supercritical Fluids;2024-05

5. Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease and Potential for Pathogenetic Therapy;Neuroscience and Behavioral Physiology;2024-05